<h4>Background</h4>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual agonists have been shown to induce histological improvements in patients with metabolic dysfunction-associated steatohepatitis (MASH). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.